C. R. Bard (NYSE: BCR) today announced that a U.S. District Court jury in Arizona decided that certain of W. L. Gore & Associates Inc.'s ePTFE vascular grafts and stent-grafts willfully infringe on Bard's patent number 6,436,135. The jury found that the validity of Bard's claim against W. L. Gore was legitimate and would award $185 million to Bard in past damages. As the trial goes on, the court is currently assessing Gore's counter that Bard's patent is unenforceable due to inequitable content.After the jury's final decision, Bard expects Gore to file for post-trial motions with the court in order to attempt to take the case to the Court of Appeals for the Federal Circuit.
Wednesday, December 12, 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment